Document is current
Any future updates will be listed below
-
Authors
André, Thierry https://orcid.org/0000-0002-5103-7095
Van Cutsem, Eric https://orcid.org/0000-0002-6372-1230
Taieb, Julien https://orcid.org/0000-0002-9955-4753
Fakih, Marwan https://orcid.org/0000-0002-6554-5488
Prager, Gerald W. https://orcid.org/0000-0002-7854-7781
Ciardiello, Fortunato https://orcid.org/0000-0002-3369-4841
Falcone, Alfredo https://orcid.org/0000-0001-5840-2529
Saunders, Mark https://orcid.org/0000-0002-7195-4712
Amellal, Nadia
Roby, Lucas
Tabernero, Josep https://orcid.org/0000-0002-2495-8139
Pfeiffer, Per https://orcid.org/0000-0002-2925-0586
- License Information
-
More Information
Article History
Accepted: 26 August 2024
First Online: 26 September 2024
Declarations
:
: Thierry André reports attending advisory board meetings and receiving consulting fees from Abbvie, Astellas, Aptitude Health, Bristol Myers Squibb, Gritstone Oncology, Gilead, GlaxoSmithKline, Merck & Co. Inc., Nordic Oncology, Seagen, Servier, Takeda and honoraria from Bristol Myers Squibb, GlaxoSmithKline, Merck & Co. Inc., Merck Serono, Roche, Sanofi, Seagen and Servier; and a DMC member role for Inspirna and support for meetings from Bristol Myers Squibb, Merck & Co. Inc. and Servier. Eric Van Cutsem participated in advisory boards for Abbvie, ALX, Amgen, Array, Astellas, Astrazeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seattle Genetics, Servier, Takeda, Terumo, Taiho, Zymeworks and received research grants from Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier paid to his institution. Julien Taieb has received fees for advisory/consultancy roles from Lilly, MSD, Amgen, Merck Serono, Novartis, Roche, Sanofi, Servier, HalioDX SAS and Pierre Fabre. Marwan Fakih has received honoraria from Amgen, has received fees for speaker, consultancy or advisory roles from Amgen, Array BioPharma, Bayer, Guardant360 and Pfizer, and has received research grant support from Amgen, Novartis and AstraZeneca. Gerald Prager has provided consulting/advisory for Amgen, Daiichi Sanyo Europe GmbH, Incyte, Merck Serono, Pierre Fabre, Roche/Genetech, Servier, Lilly O., AstraZeneca, Arcus Bioscience, and Bayer US LLC Fortunato Ciardiello has provided consulting/advisory for Amgen, Merck KGaA, Pfizer, Roche/Genentech, Bayer US, LLC; and received research funding from Amgen, BMS, Ipsen, Merck KGaA, Merck Sharp & Dome, Roche/Genetech, Servier, Symphogen; Bayer US, LLC. Alfredo Falcone: reports no conflict of interest. Mark Saunders reports advisory role or speaking for Takeda, Bayer, GSK, MSD and Servier. Nadia Amellal and Lucas Roby are employees of Servier. Joseph Tabernero has provided consulting/advisory for Alentis Therapeutics, Amgen, AstraZeneca, Aveo Oncology, Boehringer Ingelheim, Cardiff Oncology, CARSgen Therapeutics, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, hC Bioscience, Immodulon Therapeutics, Inspirna Inc, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Takeda Oncology and Tolremo Therapeutics. Stocks: Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP. Educational collaboration: Medscape Education, PeerView Institute for Medical Education and Physicians Education Resource (PER). Per Pfeiffer reports advisory role or speaking for Servier.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
